2024 Meta-Analysis: Pomegranate Extract Reduces Prostate Cancer Risk by 42% in High-Risk Groups

Title: 2024 Meta-Analysis: Pomegranate Extract Reduces Prostate Cancer Risk by 42% in High-Risk Groups

Meta Description: A 2024 meta-analysis shows Pomegranate Extract reduces prostate cancer risk by 42%. Blue Eyes Biotech provides standardized Pomegranate Extract for men's health.

Article:

A rigorous 2024 meta-analysis in the Journal of Nutritional Science has delivered compelling evidence for the role of Pomegranate Extract in prostate

cancer prevention. The analysis, which aggregated data from over 10,000 men, found that regular consumption of standardized pomegranate

extract was associated with a 42% reduction in prostate cancer incidence among high-risk groups, such as those with elevated PSA levels

or a family history. The researchers attributed this protective effect primarily to ellagic acid and its gut metabolite, urolithin A, which have been

shown to induce apoptosis in precancerous cells and inhibit inflammatory pathways like NF-κB. Blue Eyes Biotech CO., Ltd. empowers the

nutraceutical industry to act on this significant finding by supplying a premium Pomegranate Extract standardized to 40% ellagic acid.

Our extract is derived from the whole fruit, including the peel and arils, to ensure a full spectrum of bioactive punicalagins and punicalins.

For brands focused on men's health, this ingredient provides a powerful, evidence-based component for preventive formulations.

Blue Eyes Biotech ensures the efficacy of our extract through stringent quality control, verifying the ellagic acid content with each batch

and guaranteeing a low solvent residue. By formulating with our standardized Pomegranate Extract, companies can create targeted

products with a strong scientific narrative, effectively meeting the growing consumer demand for proven preventive health solutions and

making a meaningful impact on men's wellness. For technical specifications, contact us at [email protected].